ALLEGRIA

ALLEGRIA Therapeutics AG, founded in Basel, Switzerland, in 2023 by Forty51 Ventures, plans to develop a differentiated proprietary portfolio of treatments targeting selective modulation of mast cell biological targets, redefining the therapeutic landscape for allergies and mast cell-mediated inflammatory diseases.